Evidence map›Paper›PMID 28955932›Full record

ArticleBiochemistry and biophysics reports2016

UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance.

Hazel Tumelo Mufhandu, Kabamba Bankoledi Alexandre, Elin Solomonovna Gray, Lynn Morris, Makobetsa Khati

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hazel Tumelo MufhanduEmerging Health Technologies Platform, Biosciences Unit, CSIR, Pretoria, South Africa.
Kabamba Bankoledi AlexandreEmerging Health Technologies Platform, Biosciences Unit, CSIR, Pretoria, South Africa.
Elin Solomonovna GrayCenter for HIV and STI's, National Institute for Communicable Diseases, Johannesburg, South Africa.
Lynn MorrisCenter for HIV and STI's, National Institute for Communicable Diseases, Johannesburg, South Africa.
Makobetsa KhatiEmerging Health Technologies Platform, Biosciences Unit, CSIR, Pretoria, South Africa.
National Institute for Communicable DiseasesGroote Schuur Hospital · ZA

Funding

Aptamer Microbicide Development Program (MDP)U01AI066734 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCGOWAN, IAN MICHAEL · 2005 to 2009
$3.2M
NIAID NIH HHS U01 AI066734
6 · The paper itself

Abstract

We have previously shown that the aptamer, UCLA1, is able to inhibit HIV-1 replication in peripheral blood mononuclear cells (PBMCs) by binding to residues in gp120. In this study we examined whether UCLA1 was effective against HIV-1 subtype C isolates in monocyte-derived macrophages (MDMs). Of 4 macrophage-tropic isolates tested, 3 were inhibited by UCLA1 in the low nanomolar range (IC

Indexed as

Aptamergp120 MutationsHIV-1Monocyte-derived macrophagesSubtype CUCLA1

Identifiers

PMID28955932
PMCPMC5613508
OpenAlexW2471098085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.